Clinical Research Directory
Browse clinical research sites, groups, and studies.
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
Sponsor: Ruijin Hospital
Summary
The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G polymorphism as predictive biomarker
Official title: A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma
Key Details
Gender
All
Age Range
8 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-10-30
Completion Date
2027-09-01
Last Updated
2025-05-14
Healthy Volunteers
No
Conditions
Interventions
Apatinib monotherapy
patients will receive Apatinib 250mg tablet by mouth, bid.
Locations (1)
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China